Trafficking and functions of bioactive sphingolipids: Lessons from cells and model membranes

Lipid Insights

Volumn 2015, Issue , 2015, Pages 11-20

  Zhou, Kecheng ^a   Blom, Tomas ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ceramide; Ceramide 1 phosphate; Lipid trafficking; Membrane; Sphingosine; Sphingosine 1 phosphate

Indexed keywords

ABC TRANSPORTER; CERAMIDE; CERAMIDE 1 PHOSPHATE; CERAMIDE KINASE; G PROTEIN COUPLED RECEPTOR; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE;

APOPTOSIS; ARTICLE; ARTIFICIAL MEMBRANE; AUTOPHAGY; CELLS; CELLULAR DISTRIBUTION; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EXOCYTOSIS; HUMAN; LIPID TRANSPORT; LYSOSOME STORAGE DISEASE; MEMBRANE TRANSPORT; NEUROPATHY; NONHUMAN; SECOND MESSENGER; SPHINGOLIPID METABOLISM;

EID: 84982711441     PISSN: None     EISSN: 11786353     Source Type: Journal    
DOI: 10.4137/LPI.S31615     Document Type: Article

References (140)

1. Hannun YA, Loomis CR, Merrill AH, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem. 1986;261(27):12604-12609.
2. Goodemote KA, Mattie ME, Berger A, Spiegel S. Involvement of a pertussis toxin-sensitive G protein in the mitogenic signaling pathways of sphingosine 1-phosphate. J Biol Chem. 1995;270(17):10272-10277.
3. Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998;279(5356):1552-1555.
4. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4(8):604-616.
5. Sot J, Goñi FM, Alonso A. Molecular associations and surface-active properties of short- and long-N-acyl chain ceramides. Biochim Biophys Acta. 2005;1711(1): 12-19.
6. Bai J, Pagano RE. Measurement of spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in lipid vesicles. Biochemistry. 1997;36(29): 8840-8848.
7. López-Montero I, Rodriguez N, Cribier S, Pohl A, Vélez M, Devaux PF. Rapid transbilayer movement of ceramides in phospholipid vesicles and in human erythrocytes. J Biol Chem. 2005;280(27):25811-25819.
8. Silva L, de Almeida RF, Fedorov A, Matos AP, Prieto M. Ceramide-platform formation and -induced biophysical changes in a fluid phospholipid membrane. Mol Membr Biol. 2006;23(2):137-148.
9. Holopainen JM, Lehtonen JY, Kinnunen PK. Lipid microdomains in dimyristoylphosphatidylcholine- ceramide liposomes. Chem Phys Lipids. 1997;88(1):1-13.
10. Huang HW, Goldberg EM, Zidovetzki R. Ceramide induces structural defects into phosphatidylcholine bilayers and activates phospholipase A2. Biochem Biophys Res Commun. 1996;220(3):834-838.
11. Veiga MP, Arrondo JL, Goñi FM, Alonso A. Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys J. 1999;76(1 pt 1):342-350.
12. Karttunen M, Haataja MP, Säily M, Vattulainen I, Holopainen JM. Lipid domain morphologies in phosphatidylcholine-ceramide monolayers. Langmuir. 2009;25(8):4595-4600.
13. Ekman P, Maula T, Yamaguchi S, et al. Formation of an ordered phase by ceramides and diacylglycerols in a fluid phosphatidylcholine bilayer-correlation with structure and hydrogen bonding capacity. Biochim Biophys Acta. 2015;1848 (10 pt A):2111-2117.
14. Grassme H, Jekle A, Riehle A, et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem. 2001;276(23):20589-20596.
15. Grassmé H, Cremesti A, Kolesnick R, Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene. 2003;22(35):5457-5470.
16. Grassmé H, Bock J, Kun J, Gulbins E. Clustering of CD40 ligand is required to form a functional contact with CD40. J Biol Chem. 2002;277(33):30289-30299.
17. Grassme H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J Immunol. 2002;168(1):298-307.
18. Maula T, Artetxe I, Grandell P-M, Slotte JP. Importance of the sphingoid base length for the membrane properties of ceramides. Biophys J. 2012;103(9): 1870-1879.
19. Ruiz-Argüello MB, Basáñez G, Goñi FM, Alonso A. Different effects of enzyme-generated ceramides and diacylglycerols in phospholipid membrane fusion and leakage. J Biol Chem. 1996;271(43):26616-26621.
20. Montes LR, Ruiz-Argüello MB, Goñi FM, Alonso A. Membrane restructuring via ceramide results in enhanced solute efflux. J Biol Chem. 2002;277(14): 11788-11794.
21. Siskind LJ, Colombini M. The lipids C2- and C16-ceramide form large stable channels. Implications for apoptosis. J Biol Chem. 2000;275(49):38640-38644.
22. Siskind LJ, Kolesnick RN, Colombini M. Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations. Mitochondrion. 2006;6(3):118-125.
23. Siskind LJ, Kolesnick RN, Colombini M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J Biol Chem. 2002;277(30):26796-26803.
24. Siskind LJ, Feinstein L, Yu T, et al. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J Biol Chem. 2008;283(11):6622-6630.
25. Stiban J, Fistere D, Colombini M. Dihydroceramide hinders ceramide channel formation: implications on apoptosis. Apoptosis. 2006;11(5):773-780.
26. Contreras F-X, Basañez G, Alonso A, Herrmann A, Goñi FM. Asymmetric addition of ceramides but not dihydroceramides promotes transbilayer (flip-flop) lipid motion in membranes. Biophys J. 2005;88(1):348-359.
27. Kumagai K, Yasuda S, Okemoto K, Nishijima M, Kobayashi S, Hanada K. CERT mediates intermembrane transfer of various molecular species of ceramides. J Biol Chem. 2005;280(8):6488-6495.
28. Kudo N, Kumagai K, Tomishige N, et al. Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. Proc Natl Acad Sci U S A. 2008;105(2):488-493.
29. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009;50(suppl):S91-S96.
30. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1-23.
31. Duan RD, Cheng Y, Hansen G, et al. Purification, localization, and expression of human intestinal alkaline sphingomyelinase. J Lipid Res. 2003;44(6):1241-1250.
32. Andhoff BKS, Sandhoff K. My journey into the world of sphingolipids and sphingolipidoses. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(10):554-582.
33. Schissel SL. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem. 1998;273(5):2738-2746.
34. Jenkins RW, Canals D, Idkowiak-Baldys J, et al. Regulated secretion of acid sphingomyelinase: implications for selectivity of ceramide formation. J Biol Chem. 2010;285(46):35706-35718.
35. Tam C, Idone V, Devlin C, et al. Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J Cell Biol. 2010;189(6):1027-1038.
36. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian neutral sphingomyelinase. Proc Natl Acad Sci U S A. 2000;97(11): 5895-5900.
37. Mizutani Y, Tamiya-Koizumi K, Nakamura N, Kobayashi M, Hirabayashi Y, Yoshida S. Nuclear localization of neutral sphingomyelinase 1: biochemical and immunocytochemical analyses. J Cell Sci. 2001;114(pt 20):3727-3736.
38. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Krönke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tailanchored protein. J Biol Chem. 2006;281(19):13784-13793.
39. Clarke CJ, Guthrie JM, Hannun YA. Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells. Mol Pharmacol. 2008;74(4):1022-1032.
40. Clarke CJ, Truong T-G, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007;282(2):1384-1396.
41. Ito H, Murakami M, Furuhata A, et al. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009; 1789(11-12):681-690.
42. Levy M, Castillo SS, Goldkorn T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun. 2006;344(3):900-905.
43. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244-1247.
44. Guo BB, Bellingham SA, Hill AF. The neutral sphingomyelinase pathway regulates packaging of the prion protein into exosomes. J Biol Chem. 2015;290(6): 3455-3467.
45. Auer-Grumbach M. Hereditary sensory neuropathy type I. Orphanet J Rare Dis. 2008;3(Hsn I):7.
46. Houlden H, King R, Blake J, et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain. 2006;129(pt 2):411-425.
47. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit- 1, cause hereditary sensory neuropathy type I. Nat Genet. 2001;27:309-312.
48. Bejaoui K, Wu C, Scheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001;27(3):261-262.
49. McCampbell A, Truong D, Broom DC, et al. Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy. Hum Mol Genet. 2005;14(22):3507-3521.
50. Gillard BK, Clement RG, Marcus DM. Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways. Glycobiology. 1998;8(9):885-890.
51. Kroesen BJ, Jacobs S, Pettus BJ, et al. BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J Biol Chem. 2003;278(17):14723-14731.
52. Schiffmann S, Ziebell S, Sandner J, et al. Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide. Biochem Pharmacol. 2010;80(11):1632-1640.
53. Koybasi S, Senkal CE, Sundararaj K, et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem. 2004;279(43):44311-44319.
54. Koivusalo M, Jansen M, Somerharju P, Ikonen E. Endocytic trafficking of sphingomyelin depends on its acyl chain length. Mol Biol Cell. 2007;18(12):5113-5123.
55. Hanada K, Kumagai K, Yasuda S, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature. 2003;426(6968):803-809.
56. Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007;11(6):498-512.
57. Lee AJ, Roylance R, Sander J, et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol. 2012;226:482-494.
58. Stiban J, Caputo L, Colombini M. Ceramide synthesis in the endoplasmic reticulum can permeabilize mitochondria to proapoptotic proteins. J Lipid Res. 2008;49(3):625-634.
59. Siskind LJ. Mitochondral ceramide and the induction of apoptosis. J Bioenerg Biomembr. 2005;37(3):143-153.
60. Liu Z, Xia Y, Li B, et al. Induction of ER stress-mediated apoptosis by ceramide via disruption of ER Ca 2 + homeostasis in human adenoid cystic carcinoma cells. Cell Biosci. 2014;4:71.
61. Tafesse FG, Vacaru AM, Bosma EF, et al. Sphingomyelin synthase-related protein SMSr is a suppressor of ceramide-induced mitochondrial apoptosis. J Cell Sci. 2014;127(pt 2):445-454.
62. Chipuk JE, McStay GP, Bharti A, et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell. 2012;148(5):988-1000.
63. Lee YG, Lee J, Cho JY. Cell-permeable ceramides act as novel regulators of U937 cell-cell adhesion mediated by CD29, CD98, and CD147. Immunobiology. 2010;215(4):294-303.
64. Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci U S A. 2008;105(45):17402-17407.
65. Sentelle RD, Senkal CE, Jiang W, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol. 2012;8(10):831-838.
66. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer. 2000;29(2):137-146.
67. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008; 112(3):770-781.
68. Eliyahu E, Park J-H, Shtraizent N, He X, Schuchman EH. Acid ceramidase is a novel factor required for early embryo survival. FASEB J. 2007;21(7):1403-1409.
69. Liu X, Elojeimy S, El-Zawahry AM, et al. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006;14(5):637-646.
70. Holman DH, Turner LS, El-Zawahry A, et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008;61(2):231-242.
71. Bedia C, Casas J, Andrieu-Abadie N, Fabriàs G, Levade T. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine. J Biol Chem. 2011;286(32):28200-28209.
72. Morales A, París R, Villanueva A, Llacuna L, García-Ruiz C, Fernández- Checa JC. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene. 2007;26(6):905-916.
73. Jun G, Canquan Z, Renli Z. RNA interference targeted on SMPD1 protect human granulose cells from apoptosis. Fertil Steril. 2007;88:S337.
74. Claus RA, Bunck AC, Bockmeyer CL, et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J. 2005;19(12):1719-1721.
75. Blom T, Li Z, Bittman R, Somerharju P, Ikonen E. Tracking sphingosine metabolism and transport in sphingolipidoses: NPC1 deficiency as a test case. Traffic. 2012;13(9):1234-1243.
76. Blom T, Li S, Dichlberger A, et al. LAPTM4B facilitates late endosomal ceramide export to control cell death pathways. Nat Chem Biol. 2015;11(10):799-806.
77. Stock RP, Brewer J, Wagner K, et al. Sphingomyelinase D activity in model membranes: structural effects of in situ generation of ceramide-1-phosphate. PLoS One. 2012;7(4):e36003.
78. Kooijman EE, Sot J, Montes LR, et al. Membrane organization and ionization behavior of the minor but crucial lipid ceramide-1-phosphate. Biophys J. 2008;94(11):4320-4330.
79. Morrow MR, Helle A, Perry J, Vattulainen I, Wiedmer SK, Holopainen JM. Ceramide-1-phosphate, in contrast to ceramide, is not segregated into lateral lipid domains in phosphatidylcholine bilayers. Biophys J. 2009;96(6):2216-2226.
80. Kooijman EE, Vaknin D, Bu W, et al. Structure of ceramide-1-phosphate at the air-water solution interface in the absence and presence of Ca2+. Biophys J. 2009;96(6):2204-2215.
81. Lamour NF, Subramanian P, Wijesinghe DS, Stahelin RV, Bonventre JV, Chalfant CE. Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis. J Biol Chem. 2009; 284(39):26897-26907.
82. Stahelin RV, Subramanian P, Vora M, Cho W, Chalfant CE. Ceramide- 1-phosphate binds group IVA cytosolic phospholipase a2 via a novel site in the C2 domain. J Biol Chem. 2007;282(28):20467-20474.
83. Ward KE, Bhardwaj N, Vora M, Chalfant CE, Lu H, Stahelin RV. The molecular basis of ceramide-1-phosphate recognition by C2 domains. J Lipid Res. 2013; 54(3):636-648.
84. Simanshu DK, Kamlekar RK, Wijesinghe DS, et al. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature. 2013; 500(7463):463-467.
85. Sugiura M, Kono K, Liu H, et al. Ceramide kinase, a novel lipid kinase molecular cloning and functional characterization. J Biol Chem. 2002;277(26):23294-23300.
86. Lamour NF, Stahelin RV, Wijesinghe DS, et al. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. J Lipid Res. 2007;48(6):1293-1304.
87. Wijesinghe DS, Massiello A, Subramanian P, Szulc Z, Bielawska A, Chalfant CE. Substrate specificity of human ceramide kinase. J Lipid Res. 2005;46(12): 2706-2716.
88. Graf C, Zemann B, Rovina P, et al. Neutropenia with impaired immune response to Streptococcus pneumoniae in ceramide kinase-deficient mice. J Immunol. 2008;180(5):3457-3466.
89. Pettus BJ, Bielawska A, Spiegel S, Roddy P, Hannun YA, Chalfant CE. Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem. 2003;278(40):38206-38213.
90. Subramanian P, Stahelin RV, Szulc Z, Bielawska A, Cho W, Chalfant CE. Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2 alpha and enhances the interaction of the enzyme with phosphatidylcholine. J Biol Chem. 2005;280(18):17601-17607.
91. Gangoiti P, Bernacchioni C, Donati C, et al. Ceramide 1-phosphate stimulates proliferation of C2C12 myoblasts. Biochimie. 2012;94(3):597-607.
92. Gomez-Muñoz A, Frago LM, Alvarez L, Varela-Nieto I. Stimulation of DNA synthesis by natural ceramide 1-phosphate. Biochem J. 1997;325(pt 2):435-440.
93. Gangoiti P, Granado MH, Wang SW, Kong JY, Steinbrecher UP, Gómez-Muñoz A. Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways. Cell Signal. 2008;20(4):726-736.
94. Gómez-Muñoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J Lipid Res. 2004;45(1):99-105.
95. Granado MH, Gangoiti P, Ouro A, et al. Ceramide 1-phosphate (C1P) promotes cell migration involvement of a specific C1P receptor. Cell Signal. 2009;21(3): 405-412.
96. Pewzner-Jung Y, Tavakoli Tabazavareh S, Grassmé H, et al. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa. EMBO Mol Med. 2014;6(9):1205-1214.
97. Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med. 2008;14(11):1247-1255.
98. Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem J. 2001;359(pt 2):335-343.
99. Sasaki H, Arai H, Cocco MJ, White SH. pH dependence of sphingosine aggregation. Biophys J. 2009;96(7):2727-2733.
100. López-García F, Micol V, Villalaín J, Gómez-Fernández JC. Interaction of sphingosine and stearylamine with phosphatidylserine as studied by DSC and NMR. Biochim Biophys Acta. 1993;1153(1):1-8.
101. Contreras F-X, Sot J, Alonso A, Goñi FM. Sphingosine increases the permeability of model and cell membranes. Biophys J. 2006;90(11):4085-4092.
102. Deguchi H, Yegneswaran S, Griffin JH. Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem. 2004;279(13):12036-12042.
103. Siskind LJ, Fluss S, Bui M, Colombini M. Sphingosine forms channels in membranes that differ greatly from those formed by ceramide. J Bioenerg Biomembr. 2005;37(4):227-236.
104. Ullio C, Casas J, Brunk UT, et al. Sphingosine mediates TNFa-induced lysosomal membrane permeabilization and ensuing programmed cell death in hepatoma cells. J Lipid Res. 2012;53(6):1134-1143.
105. Lloyd-Evans E, Platt FM. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic. 2010;11(4):419-428.
106. Rodriguez-Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT. Free sphingoid bases in tissues from patients with type C Niemann-Pick disease and other lysosomal storage disorders. Biochim Biophys Acta. 1994;1226(2):138-144.
107. te Vruchte D, Speak AO, Wallom KL, et al. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest. 2014;124(3): 1320-1328.
108. García-Pacios M, Collado MI, Busto JV, et al. Sphingosine-1-phosphate as an amphipathic metabolite: its properties in aqueous and membrane environments. Biophys J. 2009;97(5):1398-1407.
109. Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254-1257.
110. Panneer Selvam S, De Palma RM, Oaks JJ, et al. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci Signal. 2015;8(381):ra58.
111. Ohkawa R, Kurano M, Mishima Y, et al. Possible involvement of sphingomyelin in the regulation of the plasma sphingosine 1-phosphate level in human subjects. Clin Biochem. 2015;48(10-11):690-697.
112. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKCdependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem. 2002;277(38):35257-35262.
113. Paugh BS, Paugh SW, Bryan L, et al. EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells. FASEB J. 2008;22(2):455-465.
114. Olivera A. Sphingosine kinase expression increases intracellular sphingosine- 1-phosphate and promotes cell growth and survival. J Cell Biol. 1999;147(3): 545-558.
115. Ding G, Sonoda H, Yu H, et al. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem. 2007;282(37):27493-27502.
116. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278(47):46832-46839.
117. Ghosh TK, Bian J, Gill DL. Intracellular calcium release mediated by sphingosine derivatives generated in cells. Science. 1990;248(4963):1653-1656.
118. Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084-1088.
119. Blom T, Bergelin N, Meinander A, et al. An autocrine sphingosine-1-phosphate signaling loop enhances NF-kappaB-activation and survival. BMC Cell Biol. 2010;11(1):45.
120. Siehler S, Wang Y, Fan X, Windh RT, Manning DR. Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J Biol Chem. 2001;276(52):48733-48739.
121. Hammad SM, Crellin HG, Wu BX, Melton J, Anelli V, Obeid LM. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat. 2008;85(3-4):107-114.
122. Xiong Y, Lee HJ, Mariko B, et al. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem. 2013;288(45):32563-32573.
123. Venkataraman K, Thangada S, Michaud J, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006; 397(3):461-471.
124. Ancellin N, Colmont C, Su J, et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem. 2002;277(8):6667-6675.
125. Hammad SM, Taha TA, Nareika A, Johnson KR, Lopes-Virella MF, Obeid LM. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat. 2006;79(1-2):126-140.
126. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006;103(44):16394-16399.
127. Sato K, Malchinkhuu E, Horiuchi Y, et al. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J Neurochem. 2007;103(6): 2610-2619.
128. Murata N, Sato K, Kon J, Tomura H, Okajima F. Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem. 2000; 282(1):115-120.
129. Yatomi Y, Igarashi Y, Yang L, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem. 1997;121(5):969-973.
130. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptormediated actions. Biochem J. 2000;352(pt 3):809-815.
131. Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science. 2009;323(5913):524-527.
132. Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J Biol Chem. 2011;286(3): 1758-1766.
133. Adada MM, Canals D, Jeong N, et al. Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrinradixin- moesin phosphorylation and cancer cell invasion. FASEB J. 2015;29(11): 4654-4669.
134. Laurenzana A, Cencetti F, Serratì S, et al. Endothelial sphingosine kinase/ SPNS2 axis is critical for vessel-like formation by human mesoangioblasts. J Mol Med (Berl). 2015;93(10):1145-1157
135. Degagné E, Pandurangan A, Bandhuvula P, et al. Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 2014;124(12):5368-5384.
136. Bradley E, Dasgupta S, Jiang X, et al. Critical role of Spns2, a sphingosine- 1-phosphate transporter, in lung cancer cell survival and migration. PLoS One. 2014;9(10):e110119.
137. Chen J, Ingham N, Kelly J, et al. Spinster homolog 2 (spns2) deficiency causes early onset progressive hearing loss. PLoS Genet. 2014;10(10):e1004688.
138. Mendoza A, Bréart B, Ramos-Perez WD, et al. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep. 2012;2(5):1104-1110.
139. Huang Y, Lemieux MJ, Song J, Auer M, Wang D-N. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science. 2003; 301(5633):616-620.
140. Hanson MA, Roth CB, Jo E, et al. Crystal structure of a lipid G protein-coupled receptor. Science. 2012;335(6070):851-855.